Patient description: Fernandez is a 41 year man who is a professional soccer player. He came to the clinic with itchy foot. Physical exam revealed localized scaling and maceration between the third and fourth of his right toe. It became inflamed and sore, with mild fissuring. The dorsum and sole of the foot was unaffected. There is no pus or tearing in the affected area. He didn't use ant topical ointment on the lesion and has no positive history for any underlying disease such as DM. He smokes 15 cigarettes per day and drinks a beer per day. His family history is positive for hyperlipidemia in her mother and MI in her father. He is in relation with several partners and use condom during the intercourse. His physical exam and lab studies were normal otherwise. Tinea pedis infection confirmed as his diagnosis by the observation of segmented fungal hyphae during a microscopic KOH wet mount examination.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Diabetes Diabetic Foot Ulcer Non-healing Wound Men and women 18 years of age, inclusive 2. Female subjects of childbearing potential must agree to practice birth control for the duration of the study 3. Documented Type 1 or Type 2 Diabetes Mellitus 4. HgbA1C ≤ 10.0% 5. Ankle:brachial blood pressure index (ABI) of 0.7 to 1.3 If ABI is > 1.3 (i.e., non-compressible ankle vessels) or cannot be measured, then Toe brachial index (TBI) of ≥ 0.5, or Doppler arterial waveforms that are triphasic or biphasic at the ankle of affected leg If ABI and TBI cannot be measured, then Transcutaneous pressure (TcpO2) of ≥ 40 around ulcer site, or Skin perfusion pressure > 30 if neither ABI, TBI, nor TcpO2 can be measured near ulcer 6. Stable medications for 2 weeks prior to Study Treatment Day 0 Sliding scale insulin permitted Select antimicrobial therapies can be used as needed 7. Capable and willing to attend the scheduled visits and comply with study procedures 8. Signed informed consent form (ICF) for study enrollment WOUND-SPECIFIC 9. Full-thickness ulcer on the foot of 1.0 cm^2 0 cm^2 at Screening Visit after debridement with no clinical signs and symptoms of infection. Full thickness is defined as penetrating the dermis, but not extending beyond the subcutaneous tissue. 10. Study ulcer has been present for at least 4 weeks but not more than 1 year  Pregnant or nursing women 2. Prisoners 3. Abnormal laboratory value(s) for routine blood work that the Clinical Investigator deems would not be in the subject's best interest to participate 4. Osteomyelitis in the study ulcer foot in the last 30 days 5. Grade 3 or 4 lower extremity edema 6. Unable to tolerate off-loading 7. Active Charcot's foot 8. History of malignancy in previous 5 years, except for basal cell carcinoma that has been treated with local excision and is no longer present 9. Patients with unstable chronic renal disease or requiring dialysis 10. Gangrene in any part of study ulcer foot 11. Patients with a history of above or below-knee amputation in the contralateral leg related to underlying chronic disease History of toe amputation in either leg would not be exclusionary. 12. Patients with history of poor compliance 13. Patients with baseline panel reactive antibody (PRA) of ≥ 20% 14. Oral or parenteral corticosteroids, immunosuppressants, radiation therapy or chemotherapy within 30 days prior to study enrollment 15. Use of an investigational product within the preceding 60 days STUDY ULCER 16. Signs and symptoms of clinical infection at study ulcer site 17. Study ulcer requiring antimicrobial therapy at Screening Visit or Study Treatment Day 0 due to clinical suspicion of infection 18. Treatment of study ulcer with Regranex® or hyperbaric oxygen within preceding 30 days 19. Previous treatment of study ulcer with any cell and/or tissue product (CTP) therapy 20. Change in wound size (increase/decrease) greater than 25% from Screening Visit to Study Treatment Day 0 21. Other ulcers within 3 cm of study ulcer 22. Ulcers with tendon, muscle, joint capsule, or bone exposure